AM-PHARMA COMPLETES ENROLLMENT IN PHASE 2 STUDY OF ILOFOTASE ALFA FOR PREVENTION OF CARDIAC SURGERY-ASSOCIATED RENAL DAMAGE

/in , /by

Utrecht, The Netherlands, October 2, 2025 – AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of cardiac surgery-associated renal damage (CSA-RD). CSA-RD, a common cause of Acute Kidney Injury (AKI), is a serious complication of cardiac surgery occurring […]

Read more

AM-PHARMA INITIATES PHASE 2 TRIAL OF ILOFOTASE ALFA FOR CARDIAC SURGERY-ASSOCIATED RENAL DAMAGE

/in , /by

Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication Utrecht, The Netherlands, January 16, 2024 – AM-Pharma B.V. today announced that the first patients have been treated in a […]

Read more

AM-PHARMA ANNOUNCES POSITIVE CLINICAL DATA FROM PHASE 1B STUDY EVALUATING ILOFOTASE ALFA IN HYPOPHOSPHATASIA PATIENTS

/in , /by

• Ilofotase alfa demonstrates pharmacologically relevant effect on disease specific biomarkers and a positive safety profile in adult patients with hypophosphatasia; • Data to be presented by Lothar Seefried, MD, at the American Society for Bone and Mineral Research’s Symposium on Rare Bone Diseases on Thursday, October 12, 2023 Utrecht, The Netherlands, October 11, 2023 […]

Read more

AM-PHARMA ANNOUNCES UPDATED CLINICAL DEVELOPMENT STRATEGY

/in , , /by

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage; Phase 1b study of ilofotase alfa as enzyme replacement therapy in hypophosphatasia patients being finalized, results to be announced before end of 2023; Juliane Bernholz, AM-Pharma’s Chief Operating Officer since 2019, succeeds Erik van den Berg as Chief Executive Officer. […]

Read more

AM-PHARMA PROVIDES BUSINESS UPDATE AND OUTCOME OF PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 REVIVAL STUDY

/in , /by

Phase 3 REVIVAL study stopped per recommendation of data monitoring committee after per-protocol pre-specified interim futility analysis on the study’s primary endpoint, 28-day mortality, without any safety concern. A significant reduction in Major Adverse Kidney Events by day 90 and no difference in overall mortality was observed after review of the data for all 649 […]

Read more

AM-PHARMA ANNOUNCES PUBLICATION OF IN VIVO ACUTE KIDNEY INJURY STUDY DEMONSTRATING ILOFOTASE ALFA’S DUAL PROTECTIVE MECHANISM

/in , /by

Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule Utrecht, The Netherlands, 05 July 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating […]

Read more

AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference

/in , , /by

Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th, 2022 at 8:00 AM ET. About AM-Pharma AM-Pharma’s purpose […]

Read more

400 PATIENTS HAVE BEEN ENROLLED IN AM-PHARMA’s PIVOTAL PHASE 3 STUDY OF ILOFOTASE ALFA FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

/in , , /by

Decision from the first pre-specified futility analysis at 400 patients is expected in July Utrecht, The Netherlands, April 25, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study. […]

Read more

AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect

/in , /by

Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg,  Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, are scheduled to participate in SVB Leerink’s Biopharma Private Company Connect on Tuesday, March 29th, 2022. The company will be […]

Read more

AM-PHARMA ANNOUNCES TWO PRESENTATIONS AT THE 27TH INTERNATIONAL CONFERENCE ON ADVANCES IN CRITICAL CARE NEPHROLOGY

/in , /by

The lead investigator will present an overview of AM-Pharma’s ongoing Phase 3 REVIVAL study at 11:30 AM PT (2:30 PM ET) on Thursday, March 10, 2022; and New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery will be presented in a poster session today San Diego, California and […]

Read more